Switch theme
Sign up to access all valuation multiples
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
2009
13
Last FY Revenue $0.4M
Last FY EBITDA -$4.0M
$25.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Xintela achieved revenue of $0.4M and an EBITDA of -$4.0M.
Xintela expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xintela valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$4.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -922% | XXX | XXX | XXX |
| EBIT | XXX | -$4.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -936% | XXX | XXX | XXX |
| Net Profit | XXX | -$4.0M | XXX | XXX | XXX |
| Net Margin | XXX | -930% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xintela's stock price is SEK 0 (or $0).
Xintela has current market cap of SEK 256M (or $26.4M), and EV of SEK 249M (or $25.7M).
See Xintela trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.7M | $26.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xintela has market cap of $26.4M and EV of $25.7M.
Xintela's trades at 59.1x EV/Revenue multiple, and -6.4x EV/EBITDA.
Equity research analysts estimate Xintela's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xintela's P/E ratio is not available.
See valuation multiples for Xintela and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.4M | XXX | $26.4M | XXX | XXX | XXX |
| EV (current) | $25.7M | XXX | $25.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 59.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -6.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -6.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXintela's revenue per employee in the last FY averaged $33K, while opex per employee averaged $0.3M for the same period.
Xintela's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xintela's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xintela and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -922% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 77% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 788% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1036% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xintela acquired XXX companies to date.
Last acquisition by Xintela was XXXXXXXX, XXXXX XXXXX XXXXXX . Xintela acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xintela founded? | Xintela was founded in 2009. |
| Where is Xintela headquartered? | Xintela is headquartered in Sweden. |
| How many employees does Xintela have? | As of today, Xintela has 13 employees. |
| Is Xintela publicy listed? | Yes, Xintela is a public company listed on STO. |
| What is the stock symbol of Xintela? | Xintela trades under XINT ticker. |
| When did Xintela go public? | Xintela went public in 2016. |
| Who are competitors of Xintela? | Similar companies to Xintela include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Xintela? | Xintela's current market cap is $26.4M |
| Is Xintela profitable? | Yes, Xintela is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
